AstraZeneca has escalated its legal battle against several generic-drug makers over the patent rights to its prominent cancer drug, Lynparza. On Thursday, the pharmaceutical giant filed lawsuits in New Jersey federal court against companies such as Zydus, Sandoz, Natco, and Cipla. AstraZeneca accuses these firms of infringing on patents related to Lynparza as they attempt to sell or manufacture the drug. The move represents an expansion of AstraZeneca’s efforts to protect its market share amidst growing generic competition. More details on this legal development can be found in the article by Law360.